^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    POU5F1 expression

    i
    Other names: POU5F1, OCT4, POU Class 5 Homeobox 1, POU Domain, Class 5, Transcription Factor 1, Octamer-Binding Transcription Factor 3, Octamer-Binding Protein 3, Octamer-Binding Protein 4, OTF-3, Oct-3, Oct-4, OTF3, OCT3, OCT4, POU-Type Homeodomain-Containing DNA-Binding Protein, POU Class 5 Homeobox 1 Transcript Variant OCT4B1, POU Class 5 Homeobox 1 Transcript Variant OCT4B2, POU Class 5 Homeobox 1 Transcript Variant OCT4B3, POU Class 5 Homeobox 1 Transcript Variant OCT4B4, POU Class 5 Homeobox 1 Transcript Variant OCT4B5, POU Class 5 Homeobox 1 Transcript Variant OCT4B6, POU Domain Class 5, Transcription Factor 1, POU Domain Transcription Factor OCT4, POU ClassV Homeobox 1 Variant 2, OTF4
    Entrez ID:
    5460
    Related biomarkers:
    Expression
    Fusion
    over2years
    Metabolomics analysis reveals Oct4 overexpression drives metabolic reprogramming and enhanced glycolysis and pentose phosphate pathway in lung adenocarcinoma cells. (PubMed, Biomed Chromatogr)
    This study identifies unique pathways that are candidate therapeutic targets for the treatment of lung adenocarcinoma. This study also aims to improve our understanding of the cancer-promoting activity of Oct4 and help identify novel diagnostic and therapeutic strategies for cancer treatment.
    Journal
    |
    POU5F1 (POU Class 5 Homeobox 1)
    |
    POU5F1 expression
    over2years
    Possible cytotoxic effect of allantoin on oral squamous cell carcinoma stemness (in vivo and in vitro model. (PubMed, FASEB J)
    The effect of allantoin and/or 5-fluorouracil (5FU) on cell cycle, apoptosis and expression of stem cell and apoptotic markers was tested in vitro...This was mediated by modulating stromal component of TM via down-regulation of trans-differentiation of cancer associated fibroblasts and tumor associated macrophages. These findings shed the light on potential use of allantoin as cytotoxic drug either alone or combined with other chemotherapeutic drugs.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • CD163 (CD163 Molecule) • CD44 (CD44 Molecule) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • TGFB1 (Transforming Growth Factor Beta 1) • NANOG (Nanog Homeobox)
    |
    IL6 expression • POU5F1 expression
    |
    5-fluorouracil
    over2years
    Hepatitis B Virus Pregenomic RNA Reflecting Viral Replication in Distal Non-tumor Tissues as a Determinant of the Stemness and Recurrence of Hepatocellular Carcinoma. (PubMed, Front Microbiol)
    HBV replication may present in HCC with a weak transcriptomic signature. Moreover, the expression level of HBV pgRNA in distal non-tumor tissues is a sensitive marker for HBV replication and prognosis, which is associated with CSC-related markers especially with OCT4 in distal non-tumor tissues and recurrence of HCC in HBV-related HCC patients.
    Journal
    |
    CD44 (CD44 Molecule) • POU5F1 (POU Class 5 Homeobox 1)
    |
    CD133 expression • POU5F1 expression
    over2years
    Prognostic value of NOTCH1 and OCT4 in gastric carcinoma. (PubMed, Indian J Pathol Microbiol)
    Overexpression of NOTCH1 and OCT4 correlated with poor response to chemotherapy (P = 0.013, P = 0.005, respectively) and worse clinical outcome. Combined detection of these proteins might disclose even better predictive value for shorter survival and resistance to chemotherapy.
    Journal
    |
    NOTCH1 (Notch 1) • POU5F1 (POU Class 5 Homeobox 1)
    |
    POU5F1 expression • NOTCH1 overexpression
    over2years
    OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-Resistant Breast Cancer Mice. (PubMed, Front Oncol)
    In vivo, OCT4&SOX2 CTLs plus PD-1 inhibitor (nivolumab) decreased tumor volume and tumor weight while increased tumor apoptosis rate compared to OCT4&SOX2 CTLs alone, PD-1 inhibitor (nivolumab) alone, and control. OCT4&SOX2 CTLs exhibit good efficiency and synergize PD-1 inhibitor (nivolumab) in treating BCSCs and DRBC.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • CD40LG (CD40 ligand)
    |
    POU5F1 expression
    |
    Opdivo (nivolumab)